Dr. Jeremy Ross, M.D
NPI: 1013250455
Total Payments
$347,288
2024 Payments
$149,173
Companies
37
Transactions
475
Medicare Patients
4,098
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$264,141 (76.1%)
Consulting$39,399 (11.3%)
Travel$36,084 (10.4%)
Food & Beverage$7,400 (2.1%)
Education$264.12 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $257,216 | 66 | 74.1% |
| Consulting Fee | $39,399 | 24 | 11.3% |
| Travel and Lodging | $36,084 | 170 | 10.4% |
| Food and Beverage | $7,400 | 205 | 2.1% |
| Honoraria | $6,925 | 4 | 2.0% |
| Education | $264.12 | 6 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $145,132 | 186 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $130,299 | 112 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $24,112 | 20 | $0 (2024) |
| GENZYME CORPORATION | $21,479 | 28 | $0 (2024) |
| GlaxoSmithKline, LLC. | $8,347 | 8 | $0 (2024) |
| PFIZER INC. | $5,325 | 9 | $0 (2024) |
| Kite Pharma, Inc. | $4,797 | 2 | $0 (2022) |
| Novocure Inc. | $2,600 | 1 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $1,952 | 5 | $0 (2024) |
| Daiichi Sankyo Inc. | $702.57 | 15 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149,173 | 192 | Regeneron Healthcare Solutions, Inc. ($63,216) |
| 2023 | $136,188 | 191 | E.R. Squibb & Sons, L.L.C. ($72,542) |
| 2022 | $54,383 | 75 | Regeneron Healthcare Solutions, Inc. ($37,736) |
| 2021 | $5,629 | 13 | PFIZER INC. ($2,250) |
| 2020 | $1,886 | 2 | Karyopharm Therapeutics Inc. ($1,875) |
| 2017 | $29.05 | 2 | Alexion Pharmaceuticals, Inc. ($16.56) |
All Payment Transactions
475 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,137.00 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $1.35 | General |
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $3.65 | General |
| Category: Oncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $2.55 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.92 | General |
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,605.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $103.65 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $24.57 | General |
| 11/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $4.80 | General |
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,912.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $299.03 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $258.25 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $258.25 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $107.26 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $5.21 | General |
| 11/12/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $154.58 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $80.06 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $70.71 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $36.77 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $10.51 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $155.22 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $94.13 | General |
| Category: Oncology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $35.60 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 1,228 | 42,821 | $1.3M | $283,887 |
| 2022 | 33 | 1,263 | 49,056 | $1.4M | $316,680 |
| 2021 | 36 | 1,196 | 39,788 | $1.6M | $495,599 |
| 2020 | 18 | 411 | 2,305 | $222,691 | $55,775 |
Total Patients
4,098
Total Services
133,970
Medicare Billing
$1.2M
Procedure Codes
120
All Medicare Procedures & Services
120 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 325 | $113,750 | $45,114 | 39.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 29 | 36 | $146,484 | $41,089 | 28.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 61 | 345 | $142,140 | $35,061 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 118 | 292 | $80,300 | $28,296 | 35.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 71 | 235 | $58,750 | $21,834 | 37.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 45 | 85 | $57,885 | $13,905 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 98 | 201 | $35,175 | $12,568 | 35.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 30 | 217 | $43,834 | $10,931 | 24.9% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 25 | 575 | $71,875 | $10,635 | 14.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 122 | $21,350 | $7,535 | 35.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 56 | 596 | $41,720 | $7,237 | 17.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $14,000 | $4,812 | 34.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 48 | 93 | $37,293 | $4,532 | 12.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 32 | 196 | $19,600 | $4,463 | 22.8% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 23 | 89 | $14,240 | $4,252 | 29.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 165 | $15,345 | $3,634 | 23.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 36 | 75 | $14,250 | $3,627 | 25.4% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 14 | 13,080 | $25,824 | $3,274 | 12.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $12,000 | $3,250 | 27.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 22 | 29 | $13,050 | $3,069 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $8,800 | $2,757 | 31.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 26 | 21,000 | $105,000 | $2,721 | 2.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 39 | 2,290 | $119,080 | $1,911 | 1.6% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 25 | 25 | $5,000 | $1,348 | 27.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 46 | 116 | $6,960 | $1,278 | 18.4% |
About Dr. Jeremy Ross, M.D
Dr. Jeremy Ross, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2013. The National Provider Identifier (NPI) number assigned to this provider is 1013250455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeremy Ross, M.D has received a total of $347,288 in payments from pharmaceutical and medical device companies, with $149,173 received in 2024. These payments were reported across 475 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($257,216).
As a Medicare-enrolled provider, Ross has provided services to 4,098 Medicare beneficiaries, totaling 133,970 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 120 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Fort Worth, TX
- Active Since 04/04/2013
- Last Updated 02/06/2025
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1013250455
Products in Payments
- LIBTAYO (Biological) $148,495
- OPDIVO (Biological) $104,626
- AUGTYRO (Drug) $15,643
- ENHERTU (Biological) $8,457
- Yescarta (Drug) $4,797
- Optune Lua (NovoTTF-200T) (Device) $2,600
- BOSULIF (Drug) $2,250
- Truqap (Drug) $2,055
- XPOVIO (Drug) $1,952
- IBRANCE (Drug) $1,565
- LORBRENA (Drug) $1,440
- ERLEADA (Drug) $461.02
- BLENREP (Biological) $430.00
- Enhertu (Drug) $306.47
- REBLOZYL (Biological) $257.48
- ENHERTU (Drug) $151.81
- NERLYNX (Drug) $135.93
- Neuroblate (Device) $134.65
- TRELEGY ELLIPTA (Drug) $116.68
- Ozempic (Drug) $110.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Fort Worth
Dr. Richard Teames, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $679,444
Student in an Organized Health Care Education/Training Program $679,444
Brett Mueller, Do, Phd, DO, PHD
Student in an Organized Health Care Education/Training Program — Payments: $114,196
Student in an Organized Health Care Education/Training Program $114,196
Herman Kao, Dds, Md, DDS, MD
Student in an Organized Health Care Education/Training Program — Payments: $57,014
Student in an Organized Health Care Education/Training Program $57,014
Dr. Natalia Chaimowitz, M.d., Ph.d, M.D., PH.D
Student in an Organized Health Care Education/Training Program — Payments: $40,250
Student in an Organized Health Care Education/Training Program $40,250
Dr. Joshua Payne, D.o, D.O
Student in an Organized Health Care Education/Training Program — Payments: $22,289
Student in an Organized Health Care Education/Training Program $22,289
Dr. Christopher Lafargue, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $19,847
Student in an Organized Health Care Education/Training Program $19,847